Diabetes Type II

Mesenchymal Stem Cells (MSCs) are being studied in Type 2 diabetes to investigate potential roles in glucose regulation, insulin sensitivity, and metabolic processes. 

Type 2 diabetes mellitus (T2DM) is a chronic, progressive metabolic disorder marked by a combination of insulin resistance in muscle, adipose tissue, and the liver, together with a relative deficiency in insulin secretion due to progressive pancreatic β-cell dysfunction. These mechanisms lead to sustained hyperglycemia, often accompanied by dyslipidemia, hypertension, and a prothrombotic state, forming part of the metabolic syndrome. MSC research in Type 2 diabetes is ongoing and aims to clarify whether their biological effects could support future therapeutic strategies. Evidence remains early, but this work is expanding understanding of regenerative medicine in metabolic health. 

Clinical Trials

Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial — Li Zang, et al.


 

Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow-derived mesenchymal stem/stromal cells — Liem Thanh Nguyen, et al.


 

Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study — Jay S Skyler, et al.


 

Efficacy of Autologous Bone Marrow-Derived Mesenchymal Stem Cell and Mononuclear Cell Transplantation in Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Comparative Study — Shobhit Bhansali, et al.


 

Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study — Ranhua Jiang, et al.


 

Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus — Dexiao Kong, et al.